Remaining questions in ductal carcinoma in situ

Pat W. Whitworth, MD, Vanderbilt University Medical Center, Nashville, TN, comments on additional lines of research within the field of ductal carcinoma in situ (DCIS). Previous studies have identified a number of patients with DCIS who are HER2 positive and respond to trastuzumab. Further research is subsequently required to ****ess whether patients who have a residual risk and are HER2 positive will benefit from receiving trastuzumab. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.